A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
Status:
Not yet recruiting
Trial end date:
2025-03-28
Target enrollment:
Participant gender:
Summary
An open-label study in which participants with non-segmental vitiligo with genital
involvement will apply ruxolitinib 1.5% cream twice a day (BID) to all depigmented areas (up
to 10% BSA) for up to 48 weeks. Participants should continue to treat depigmented areas
identified for treatment at baseline regardless of whether the area begins to improve or
fully repigment.